Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOT A NIGLIO

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1760828016
CMS profile
8799026
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$321.44

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $321.44 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Seagen Inc. $194.44 1
PFIZER INC. $127.00 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOT A NIGLIO

NPI 1760828016 · CMS profile ID 8799026

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760828016?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOT A NIGLIO, NPI 1760828016, CMS profile ID 8799026. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760828016?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SCOT A NIGLIO, NPI 1760828016, CMS profile ID 8799026. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760828016?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SCOT A NIGLIO, NPI 1760828016, CMS profile ID 8799026, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1760828016?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $321.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $127.0006/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049324735 CMS
Seagen Inc. $194.4402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995745373 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $961.33 1
PY2023 $321.44 2
PY2024 $442.22 4
PY2025 $304.06 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $228,125.62 4
PY2024 Principal investigator $1,291,441.34 47
PY2023 Principal investigator $1,077,803.48 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $56,440.85 12/31/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center
A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03# Substudy 03B No dispute reported 06/30/2026 1042494831
Principal investigator 1 Merck Sharp & Dohme LLC $59,923.72 12/31/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center
A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03# Substudy 03B No dispute reported 06/30/2026 1042494833
Principal investigator 1 Merck Sharp & Dohme LLC $56,439.81 12/31/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center
Phase 1b,2 study of immune and targeted combination therapies in participants with RCC No dispute reported 06/30/2026 1042495183
Principal investigator 1 Merck Sharp & Dohme LLC $88,041.94 12/31/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center
Phase 1b,2 study of immune and targeted combination therapies in participants with RCC No dispute reported 06/30/2026 1042495185
Principal investigator 1 Merck Sharp & Dohme LLC $5,664.63 12/31/2023 Non-covered Recipient Entity
Perlmutter NYU Cancer Center
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with Other Investigational Agents in Subjects with High-riskNon-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-GuerinBCG Therapy No dispute reported 06/30/2026 1042496825
Principal investigator 1 Merck Sharp & Dohme LLC $12,747.53 12/31/2023 Non-covered Recipient Entity
Perlmutter NYU Cancer Center
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with Other Investigational Agents in Subjects with High-riskNon-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-GuerinBCG Therapy No dispute reported 06/30/2026 1042496831
Principal investigator 1 Merck Sharp & Dohme LLC $38,480.60 12/31/2023 Non-covered Recipient Entity
New York University Perlmutter Cancer Center
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-866 No dispute reported 06/30/2026 1042503821
Principal investigator 1 Merck Sharp & Dohme LLC $56,944.80 12/31/2023 Non-covered Recipient Entity
New York University Perlmutter Cancer Center
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-866 No dispute reported 06/30/2026 1042503831
Principal investigator 1 Merck Sharp & Dohme LLC $31,606.12 12/31/2023 Non-covered Recipient Entity
Winthrop University Hospital
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 No dispute reported 06/30/2026 1042512691
Principal investigator 1 Merck Sharp & Dohme LLC $34,981.04 12/31/2023 Non-covered Recipient Entity
New York University Perlmutter Cancer Center
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 No dispute reported 06/30/2026 1042512859
Principal investigator 1 Merck Sharp & Dohme LLC $121,723.90 12/31/2023 Non-covered Recipient Entity
New York University Perlmutter Cancer Center
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 No dispute reported 06/30/2026 1042512869
Principal investigator 1 Merck Sharp & Dohme LLC $18,657.63 12/31/2023 Non-covered Recipient Entity
Winthrop University Hospital
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 No dispute reported 06/30/2026 1042516383
Principal investigator 1 Gilead Sciences, Inc. $200.00 12/26/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025373117
Principal investigator 1 Merck Sharp & Dohme LLC $25,191.00 12/18/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center
A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03# Substudy 03B No dispute reported 06/30/2026 1042494691
Principal investigator 1 Merck Sharp & Dohme LLC $57,048.00 12/18/2023 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center
Phase 1b,2 study of immune and targeted combination therapies in participants with RCC No dispute reported 06/30/2026 1042495181
Principal investigator 1 Merck Sharp & Dohme LLC $168,070.32 12/13/2023 Non-covered Recipient Entity
New York University Perlmutter Cancer Center
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-866 No dispute reported 06/30/2026 1042503811
Principal investigator 1 Seagen Inc. $2,180.00 12/13/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995830417
Principal investigator 1 Merck Sharp & Dohme LLC $87,416.00 12/11/2023 Non-covered Recipient Entity
New York University Perlmutter Cancer Center
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 No dispute reported 06/30/2026 1042512633
Principal investigator 1 Seagen Inc. $400.00 11/22/2023 Non-covered Recipient Entity
NYU Langone Perlmutter Cancer Center
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy with Optional Maintenance Therapy in Subjects with HER2 Expressing Previously Untreated Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995717011
Principal investigator 1 Gilead Sciences, Inc. $2,378.00 11/17/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025373111
Principal investigator 1 Gilead Sciences, Inc. $101.25 11/16/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025373105
Principal investigator 1 Seagen Inc. $60,697.50 11/15/2023 Non-covered Recipient Entity
NYU Langone Perlmutter Cancer Center
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy with Optional Maintenance Therapy in Subjects with HER2 Expressing Previously Untreated Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995716997
Principal investigator 1 Gilead Sciences, Inc. $338.00 11/01/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025373099
Principal investigator 1 Eli Lilly and Company $49,147.50 10/18/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY
AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS No dispute reported 06/30/2026 1038122234
Principal investigator 1 Merck Sharp & Dohme LLC $33,708.60 10/16/2023 Non-covered Recipient Entity
Winthrop University Hospital
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer MIBC KEYNOTE-992 No dispute reported 06/30/2026 1042516371
Principal investigator 1 Seagen Inc. $2,180.00 10/11/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995830405
Principal investigator 1 Seagen Inc. $2,377.50 09/20/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995828485
Principal investigator 1 Gilead Sciences, Inc. $1,014.00 08/02/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025373093
Principal investigator 1 Merck Sharp & Dohme LLC $163.24 07/07/2023 Non-covered Recipient Entity
Perlmutter NYU Cancer Center
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with Other Investigational Agents in Subjects with High-riskNon-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-GuerinBCG Therapy No dispute reported 06/30/2026 1042496837
Principal investigator 1 Seagen Inc. $270.00 06/21/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995829629
Principal investigator 1 Seagen Inc. $820.00 06/21/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995829639
Principal investigator 1 Seagen Inc. $820.00 06/21/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995829691
Principal investigator 1 Seagen Inc. $270.00 06/21/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995829699
Principal investigator 1 Seagen Inc. $270.00 06/21/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995829711
Principal investigator 1 Seagen Inc. $270.00 06/21/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995829721
Principal investigator 1 Seagen Inc. $820.00 06/21/2023 Non-covered Recipient Entity
NEW YORK UNIVERSITY CANCER INSTITUTE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995829731